MK-677 (Ibutamoren): What the Research Shows About This Oral GH Secretagogue

What Is MK-677?

MK-677 (ibutamoren mesylate) is an orally active growth hormone secretagogue that mimics the action of ghrelin, the body’s hunger hormone. Unlike most compounds discussed on this site, MK-677 is not technically a peptide. It is a non-peptidyl molecule that activates the ghrelin receptor (GHS-R1a) to stimulate growth hormone release from the pituitary gland.

MK-677 was developed by Merck in the 1990s and has been investigated in several clinical trials for conditions including growth hormone deficiency, sarcopenia, and osteoporosis. Despite promising early data, it has not been approved by the FDA for any indication. It remains one of the most discussed compounds in communities interested in growth hormone optimization.

What distinguishes MK-677 from injectable GH secretagogues like GHRP-6, GHRP-2, or ipamorelin is its oral bioavailability and long half-life — approximately 24 hours. This allows once-daily dosing without injections.

Who this page is for, and who it isn’t for

This page is for people who want to understand what MK-677 research has demonstrated, where clinical evidence exists, and what remains uncertain. It is written for researchers, clinicians, and informed readers evaluating the literature.

This page is not a treatment guide or buying recommendation. MK-677 is not approved for human use. If you are considering growth hormone-related therapies, consult a qualified healthcare provider.

How MK-677 Is Thought to Work

MK-677 activates the ghrelin receptor to trigger pulsatile growth hormone release, closely mimicking natural GH secretion patterns.

MK-677 binds to the growth hormone secretagogue receptor (GHS-R1a). This is the same receptor activated by the endogenous hormone ghrelin. The binding triggers the pituitary gland to release growth hormone in a pulsatile fashion, which is considered more physiological than the flat elevation produced by exogenous GH injection.

The GH release from MK-677 subsequently increases circulating levels of insulin-like growth factor 1 (IGF-1). IGF-1 mediates many of GH’s downstream effects on tissue growth and repair. In a 2-year study of elderly subjects, MK-677 increased IGF-1 levels to those of young adults and sustained this elevation throughout the study period (Nass et al., 2008).

Unlike exogenous GH, MK-677 preserves the hypothalamic-pituitary feedback axis. Growth hormone release still responds to GHRH and somatostatin modulation, though the baseline is elevated. This is mechanistically similar to how CJC-1295 and sermorelin work through GHRH pathways, except MK-677 operates through the ghrelin pathway instead.

MK-677 also increases appetite significantly in most users, an expected pharmacological effect given that it activates the same receptor as the hunger hormone ghrelin.

What the Research Shows

MK-677 has more human clinical data than most GH secretagogues, though no Phase III trials have led to FDA approval.

Growth hormone and IGF-1 elevation (human data)

Multiple clinical trials have confirmed that MK-677 reliably increases GH and IGF-1 in humans. Chapman et al. (1996) demonstrated that 25 mg/day for 14 days increased IGF-1 by approximately 40% in obese males, with GH pulsatility resembling that of younger subjects (Chapman et al., 1996).

The most substantial dataset comes from Nass et al. (2008), a 2-year randomized controlled trial in 65 healthy elderly adults. MK-677 at 25 mg/day restored IGF-1 and GH levels to young-adult ranges and maintained this effect over the full study period without tachyphylaxis (Nass et al., 2008).

Body composition (human data — mixed)

Despite consistent GH/IGF-1 elevation, body composition results have been modest. In the Nass et al. study, MK-677 increased fat-free mass by approximately 1.1 kg over 12 months but also increased fat mass slightly. The Murphy et al. (2001) trial in hip fracture patients showed improved functional measures but did not demonstrate significant muscle mass gains (Murphy et al., 2001).

This disconnect between robust GH elevation and modest body composition changes is an important finding. GH secretagogues may not produce the dramatic recomposition effects that community discussions sometimes imply. For context on how to interpret such claims, see our guide on reading peptide evidence.

Sleep quality (human data)

One of the more consistent findings across MK-677 trials is improved sleep quality. Copinschi et al. (1997) found that MK-677 increased Stage IV (deep) sleep duration by approximately 50% and REM sleep by 20% in young healthy subjects (Copinschi et al., 1997). This is frequently cited as one of the most noticeable subjective effects reported by users.

Bone density (human data — preliminary)

In the 2-year elderly study, MK-677 increased bone mineral density markers, though the increases in actual BMD were modest and the study was not powered to assess fracture risk (Nass et al., 2008).

Appetite stimulation (human data — consistent)

Increased appetite is one of the most reliable effects of MK-677 and is consistent with its mechanism as a ghrelin mimetic. This can be beneficial for individuals needing to increase caloric intake but is a significant drawback for those using it during caloric restriction.

Community-Reported Protocols

The following reflects what is discussed in online communities and does not constitute medical advice or a recommendation. Consult a healthcare provider before using any research compound.

Community discussions typically center on 10-25 mg taken orally once daily, usually before bed (to align GH release with natural nocturnal GH pulses and to manage appetite stimulation during sleep). Most users report taking it for 8-16 week cycles, though some report continuous use for months.

Common observations in community reports include improved sleep quality within the first week, increased appetite within days, mild water retention (particularly in the hands and face), and gradual improvements in recovery from exercise. The safety considerations of long-term use at these doses have not been established in clinical trials.

Users frequently discuss combining MK-677 with injectable GH secretagogues like ipamorelin or CJC-1295, though the evidence for peptide stacking is largely anecdotal.

Side Effects and Safety Considerations

MK-677’s side effect profile is relatively well-characterized from clinical trials, which is unusual for compounds in this space.

Commonly reported side effects in clinical trials include:

• Increased appetite. The most consistent effect, expected from ghrelin receptor activation.
• Mild water retention and edema. Particularly in extremities, usually transient.
• Transient increases in fasting blood glucose. MK-677 can impair insulin sensitivity.
• Lethargy/drowsiness. Often reported in the first 1-2 weeks.
• Numbness or tingling in extremities. Consistent with GH-related effects.

The insulin sensitivity concern is particularly important. In the Nass et al. study, fasting glucose increased and insulin sensitivity decreased in the MK-677 group. For individuals with pre-existing insulin resistance or diabetes risk, this warrants medical supervision.

Lower insulin sensitivity means the body becomes worse at managing blood sugar, which over time can move someone closer to diabetic thresholds without obvious symptoms.

Long-term IGF-1 elevation also raises theoretical concerns about cancer risk. IGF-1 is a growth factor that can promote cell proliferation. No clinical trial of MK-677 has demonstrated increased cancer incidence, but trials have been relatively short and not powered to detect such outcomes.

Related Peptides

If you’re researching growth hormone secretagogues, these related pages may be useful:

• Ipamorelin: the most selective injectable GH secretagogue, minimal side effects
• CJC-1295: GHRH analog, often combined with GH secretagogues
• GHRP-6: first-generation GHRP, strong appetite stimulation
• GHRP-2: second-generation GHRP, less appetite than GHRP-6
• Hexarelin: strongest acute GH release, but desensitization issues
• Sermorelin: GHRH analog, formerly FDA-approved

Frequently Asked Questions

Is MK-677 a peptide?

No. MK-677 is a non-peptidyl compound, a small molecule that happens to activate a receptor in the same pathway as peptide GH secretagogues. It is included on this site because it is frequently discussed alongside peptides like ipamorelin and GHRP-6 in growth hormone contexts.

Is MK-677 a SARM?

No, though it is frequently mislabeled as one. MK-677 does not interact with androgen receptors. It is a growth hormone secretagogue that works through the ghrelin receptor. The confusion likely arises because MK-677 is often sold alongside SARMs by research chemical vendors.

Does MK-677 suppress natural GH production?

Clinical data suggests it does not suppress endogenous GH production in the way that exogenous GH injection does. The pulsatile release pattern and preserved feedback mechanisms appear to maintain physiological regulation. Baseline GH secretion patterns may be altered during use.

How long do the effects last?

The Nass et al. 2-year study demonstrated sustained IGF-1 elevation without tachyphylaxis over the full study period, suggesting that tolerance to the GH-elevating effects does not develop with chronic use.

Does MK-677 cause hair loss?

This is not reported in clinical trials. However, elevated IGF-1 and GH can theoretically influence hair follicle cycling. Community reports on this topic are mixed and inconclusive.

Can MK-677 be taken with food?

Clinical trials administered MK-677 without specific food requirements. Community protocols vary between fasted and fed administration, with no controlled data comparing the two approaches.

References

1. Chapman IM, et al. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. PubMed

2. Nass R, et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. PubMed

3. Murphy MG, et al. (2001). Effect of ibutamoren mesylate (MK-677) on the recovery of hip fracture patients. Clin Endocrinol. PubMed

4. Copinschi G, et al. (1997). Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab. PubMed

5. Smith RG, et al. (2005). Peptidomimetic regulation of growth hormone secretion. Endocr Rev. PubMed

Related Articles

Peptide

CJC-1295: What the Evidence Says About This GHRH Analog

An evidence-first review of CJC-1295, covering how it differs from native GHRH, DAC vs no-DAC variants, clinical trial data, and what the research shows about GH stimulation.

Peptide

GHRP-2: What the Research Shows About This Second-Generation GH Secretagogue

An evidence-based review of GHRP-2 — clinical data on growth hormone release, comparisons to GHRP-6 and ipamorelin, and safety considerations.

Peptide

GHRP-6: What the Research Shows About This Growth Hormone Releasing Peptide

An evidence-based review of GHRP-6, covering research on growth hormone secretion, appetite stimulation, and how it compares to newer GH secretagogues.